Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | STK33 | Q9BYT3 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7807324 | 0.94 | IDO1 (0.43) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Acetic Acid SCHEMBL7654519 | 0.90 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Acetic Acid SCHEMBL7662840 | 0.88 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7817735 | 0.88 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Acetic Acid SCHEMBL7659851 | 0.88 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Acetic Acid SCHEMBL7655374 | 0.88 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Acetic Acid SCHEMBL8516336 | 0.87 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Acetic Acid SCHEMBL7663912 | 0.87 | CA12 (0.42) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Acetic Acid SCHEMBL7817650 | 0.86 | MEN1 (0.46) | MEN1KMT2ANPC1RAB9ASTK33 | |
| Acetic Acid SCHEMBL7662541 | 0.86 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025043-A1 | New pharmaceutical active compounds | ASTRA AKTIEBOLAG, A SWEDEN CORPORATION | 2001-09-27 | — | — | US | claimed |
| US-6271231-B1 | Pharmaceutically active compounds | ASTRA AKTIEBOLAG (SE) | 2001-08-07 | — | — | US | claimed |
| EP-0929551-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | Astra Aktiebolag (publ) (SE) | 1999-07-21 | — | — | EP | claimed |
| WO-1998013368-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRA AKTIEBOLAG (PUBL) (SE) | 1998-04-02 | — | — | WO | claimed |
| US-20010025043-A1 | New pharmaceutical active compounds | ASTRA AKTIEBOLAG, A SWEDEN CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6271231-B1 | Pharmaceutically active compounds | ASTRA AKTIEBOLAG (SE) | 2001-08-07 | — | — | US | disclosed |
| EP-0929551-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | Astra Aktiebolag (publ) (SE) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013368-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRA AKTIEBOLAG (PUBL) (SE) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025043-A1 | New pharmaceutical active compounds | CSNK1A1, CSNK1G1, CSNK2A1 | PDE4A 228/4885PDE4B 342/4885PDE4C 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.